相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Defining responders to therapies by a statistical modeling approach applied to randomized clinical trial data
Francesca Bovis et al.
BMC MEDICINE (2019)
Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS
Tjalf Ziemssen et al.
JOURNAL OF NEUROINFLAMMATION (2017)
The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
Gabriel Pardo et al.
JOURNAL OF NEUROLOGY (2017)
Laquinimod in the treatment of relapsing remitting multiple sclerosis
Undine Hainke et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor
Joel Kaye et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis
Ernst-Wilhelm Radue et al.
NEUROLOGY (2015)
Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis
Michel Varrin-Doyer et al.
EXPERIMENTAL NEUROLOGY (2014)
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis
T. L. Vollmer et al.
JOURNAL OF NEUROLOGY (2014)
Aryl Hydrocarbon Receptor Control of Adaptive Immunity
Francisco J. Quintana et al.
PHARMACOLOGICAL REVIEWS (2013)
Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination
Wolfgang Brueck et al.
ACTA NEUROPATHOLOGICA (2012)
Modulation of Autoimmune Demyelination by Laquinimod via Induction of Brain-Derived Neurotrophic Factor
Jan Thoene et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis
Rina Aharoni et al.
JOURNAL OF NEUROIMMUNOLOGY (2012)
Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
Giancarlo Comi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis
Francisco J. Quintana et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor
Francisco J. Quintana et al.
NATURE (2008)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Linomide in the treatment of multiple sclerosis:: MRI results from prematurely terminated phase-III trials
IL Tan et al.
MULTIPLE SCLEROSIS (2000)
分享论文
